Alizyme
www.alizyme.comSymbol: AZM.L
Currently trading at: 11.25p DOWN 0.75
Alizyme plc is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focused on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory bowel disease and mucositis, a serious side effect of cancer therapy.
Alizyme takes drug product candidates from an early stage into clinical development with the objective of demonstrating their efficacy in patients and providing a comprehensive data package to support the further development and commercialisation of the drug. Alizyme owns the intellectual property rights to all four drug products currently in clinical trials and has an exclusive worldwide licence to the COLAL™ drug delivery system.
At a suitable stage Alizyme aims to license its products to pharmaceutical companies that have the ability to complete the clinical development of the product, to gain approval from the regulatory authorities and to successfully market the product.
Alizyme has developed its business with a high emphasis on outsourcing, controlled by its core management team and specialist advisors. Rather than establish its own laboratories and development facilities, it has worked with collaborators and service providers such as contract research organisations. This has the benefit of allowing Alizyme to focus its investment onto its development programmes in a cost effective way.
It lised on the London Stock Exchange in 2000.
Staff
 Timothy McCarthy, Chief Executive OfficerMr McCarthy is a co-founder of Alizyme and was formerly Finance Director. He has held senior financial positions in a number of multinational companies and has founded and been instrumental in the development of a number of other biotechnology companies. |
Contact details
Great Abington
Cambridge CB1 6GX
United Kingdom
